by The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 Million in 2023 and is expected to exhibit a CAGR of 33.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Eosinophilic esophagitis is a chronic food antigen-triggered inflammatory disease of the esophagus characterized by eosinophil-predominant esophageal inflammation. It causes dysphagia and food impaction. Biologics have become the mainstay of treatment as they specifically target the eosinophilic inflammation.
Market key trends:
One of the major trends in the market includes the development of biologics for treatment of eosinophilic esophagitis. Currently, mepolizumab (brand name – Nucala) is the only FDA-approved biologic treatment option for people aged 12 years and older with EoE. Other biologics under development include dupilumab and QAX576. Dupilumab, developed by Sanofi and Regeneron Pharmaceuticals, is a monoclonal antibody inhibiting interleukin-4 (IL-4) and IL-13 signaling pathways. It is currently being evaluated in Phase 3 clinical trials for EoE. QAX576 is a humanized monoclonal antibody targeting IL-13 developed by Quantum Leap Healthcare Collaborative for treatment of EoE. It is currently in Phase 2 clinical development.
Segment Analysis
The global eosinophilic esophagitis market is segmented into treatment type and distribution channels. Based on treatment type, the market is segmented into drugs and diet modifications. The drugs segment dominated the market in 2022 and is expected to continue its dominance over the forecast period. Drugs are considered as a frontline treatment for eosinophilic esophagitis and new drug approvals and strong pipeline are further fueling the growth of this segment.
Key Takeaways
The Global Eosinophilic Esophagitis Market Share is expected to witness high growth, exhibiting a CAGR of 33% over the forecast period, due to increasing prevalence of eosinophilic esophagitis across the globe.
Regional analysis
North America is expected to dominate the global eosinophilic esophagitis market over the forecast period. Higher diagnosis rates, availability of advanced treatment options, high healthcare spending are some of the factors attributed to the large share of the region. Asia Pacific is expected to exhibit the highest growth rate during the forecast period 2023-2030 owing to growing patient awareness, improving healthcare infrastructure and healthcare expenditure.
Key players
Key players operating in the eosinophilic esophagitis market are Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
